FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Hem Securities, KR Choksey Securities Ltd and InvestorGain.com have given "Apply" recommendation to Krsnaa Diagnostics IPO. Dilip Davda has given "May Apply" recommendation to Krsnaa Diagnostics IPO. Axis Capital and JM Financial Institutional Securities have "Neutral" view about the IPO. Capital Market recommend to "Avoid" the IPO.
Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
---|---|---|---|---|---|
Count | 3 | 1 | 2 | 1 | 0 |
% | 42.86 | 14.29 | 28.57 | 14.29 | 0.00 |
Reviewer | Recommendation | Past Reviews |
---|---|---|
Axis Capital | Neutral | |
Capital Market | Avoid | |
Dilip Davda | May Apply | |
Hem Securities | Apply | |
JM Financial Institutional Securities | Neutral | |
KR Choksey Securities Ltd | Apply | |
InvestorGain.com | Apply |
The Captial Market (CapitalMarket.com) rating for Krsnaa Diagnostics IPO is 37. Their analysis recommends Do not subscribe for the IPO.
Reviewer | Rating Score | Rating |
---|---|---|
Capital Market | 37 | Do not subscribe |
[Dilip Davda] Healthcare sector counters marked hefty gains amidst pandemic scare and currently witnessing some corrections from the higher levels. KDL has posted net profits for FY21 on account of one-time gains and even with these earnings, its issue is aggressively priced at a P/E of 80+ and is thus a costly bet against listed peers. In fact, it has a negative P/E. The segment is highly fragmented with many unorganized players and also having tough competitions from organized players. Considering all these, cash surplus/risk seekers may consider investing in this highly-priced offer, others can avoid. Read detail review...
Post Recommendation Manage Recommendations
Note:
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|